B-Cell Malignancies, AML, voruciclib, venetoclax, CDK Inhibitor
Showing 1 - 25 of >10,000
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib
Recruiting
- Follicular Lymphoma (FL)
- +6 more
- voruciclib monotherapy
- voruciclib and venetoclax
-
Duarte, California
- +10 more
Aug 10, 2022
Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia
- +3 more
-
Edmonton, Alberta, Canada
- +1 more
Jan 31, 2023
Venetoclax Tablets Crushed and Dissolved Into a Solution
Not yet recruiting
- Hematologic Malignancy
- +18 more
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Nov 8, 2023
Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL) Trial in Japan (azacitadine, venetoclax,
Completed
- Non-Hodgkin Lymphoma (NHL)
- +4 more
- azacitadine
- +2 more
-
Nagoya shi, Aichi, Japan
- +13 more
Jul 29, 2021
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in
Completed
- Relapsed or Refractory Haematological Malignancies Including
- +10 more
-
Aachen, Germany
- +11 more
Oct 21, 2021
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou
Recruiting
- Allogeneic Hematopoietic Stem Cell Transplantation
- +2 more
- VEN+AZA+Modified BUCY
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Apr 10, 2023
MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)
Recruiting
- Myelodysplastic Syndromes, de Novo
- +10 more
- Venetoclax
- +10 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 23, 2023
Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Decitabine for Injection
- VENCLYXTO
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Houston (DSP107, Azacitidine, Venetoclax)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- DSP107
- +2 more
-
Houston, TexasThe University of Texas MD Anderson Cancer Center, Department of
Nov 13, 2022
Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial
Not yet recruiting
- Aggressive B-Cell Non-Hodgkin's Lymphoma
- +4 more
- (no location specified)
Dec 16, 2022
AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)
Not yet recruiting
- AML/MDS
- +2 more
- Danvatirsen
- Danvatirsen + Venetoclax
- (no location specified)
Aug 14, 2023
Lymphoma, Non-Hodgkin Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Vysis LSI MYC Break Apart Rearrangement
Recruiting
- Lymphoma
- +4 more
- Vysis LSI MYC Break Apart Rearrangement Probe Kit
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma Trial in Australia, Germany, United States
Terminated
- Acute Myeloid Leukemia
- +2 more
- Venetoclax
- AMG 176
-
Duarte, California
- +16 more
Dec 3, 2021
Acute Myeloid Leukemia Trial in Germany (Venetoclax plus Azacitidine, standard of care chemo plus gemtuzumab ozogamicin)
Not yet recruiting
- Acute Myeloid Leukemia
- Venetoclax plus Azacitidine
- standard of care chemotherapy plus gemtuzumab ozogamicin
-
Essen, NRW, Germany
- +17 more
Jun 6, 2023
Secondary Acute Myeloid Leukemia Trial in Nanjing (Venetoclax;Azacitidine;Homoharringtonine)
Recruiting
- Secondary Acute Myeloid Leukemia
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Aug 21, 2022
Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)
Not yet recruiting
- Myeloid Malignancy
- Acute Myeloid Leukemia
-
Cleveland, OhioUniversity Hospitals Seidman Cancer, Case Comprehensive Cancer C
Nov 8, 2023
Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Germany, United States (Emavusertib, Azacitidine, Venetoclax)
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Emavusertib
- +2 more
-
Tampa, Florida
- +8 more
Apr 5, 2022
AML Including AML de Novo and AML Secondary to MDS, DLBCL Trial (Birabresib Dose 20 mg)
Terminated
- AML Including AML de Novo and AML Secondary to MDS
- DLBCL
- Birabresib Dose 20 mg
- (no location specified)
Aug 23, 2022
Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)
Not yet recruiting
- Acute Myeloid Leukemia
- +6 more
-
Boston, Massachusetts
- +1 more
Mar 31, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Not yet recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 10, 2023
Acute Myeloid Leukemia Trial in Nanjing (Venetoclax-Decitabine/Azacitidine-Aclarubicin Association,
Recruiting
- Acute Myeloid Leukemia
- Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
- Venetoclax-Decitabine/Azacitidine Association
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Mar 2, 2022
AML, Adult, Chemo Effect Trial in Suzhou (Venetoclax, Decitabine for Injection, Cytarabine)
Recruiting
- AML, Adult
- Chemotherapy Effect
- Venetoclax
- +3 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Feb 28, 2022
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia
Recruiting
- Myelodysplastic Syndrome
- +2 more
- Navitoclax
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023